In a groundbreaking study, Inovio Pharmaceuticals revealed that their DNA drug candidate, INO-3107, has shown significant promise in treating recurrent respiratory papillomatosis. The Phase 1/2 clinical trial results, published in Nature Communications, indicate that 80% of the patients developed new T cell populations. This immune response is crucial as it suggests the body’s ability to fight the disease more effectively. The trial’s success rate highlights the potential of DNA-based therapies in managing chronic conditions.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
